Precision Gene Editing: Forging Disease Model Insights in Glycobiology

Gene editing-based in vivo animal model construction is the use of gene editing technology to precisely modify the animal genome to mimic human diseases or to study the function and role of specific genes. CD BioGlyco has been dedicated to Glycobiology Disease Model Development for many years, providing professional in vivo glycobiology disease model development services to clients. The Techniques we used in the in vivo glycobiology disease model development research include but are not limited to transgenic, embryo implantation and cultivation, selective breeding, gene expression, and gene editing.

• Knock in-based in vivo glycobiology disease model development service
  First, our experts work with you to confirm your research goals, targeted research disease, and desired model characteristics and develop a detailed strategy based on your requirements. Secondly, we design an appropriate gene editing program, including selection of target genes, identification of mutation types, and design of editing vectors. Thirdly, we use molecular cloning technology to construct the editing vector, insert the mutated sequence of the target gene into the vector precisely, and ensure the stability and accuracy of the vector. Finally, our experts conduct editing vector validation, in vivo gene editing, model identification and validation, and phenotyping of the edited animals, including physiological, behavioral, and molecular evaluations to determine whether the disease-related phenotypic traits have been successfully mimicked.
• Knock-down-based in vivo glycobiology disease model development service
  We first design and synthesize effective small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) that specifically target the mRNAs of target genes and reduce their expression levels. The designed siRNAs or shRNAs are then delivered to animal models by gene transfection, viral vector-mediated delivery, and chemical transfection. After the delivery of siRNA or shRNA, the changes in the expression level of the target gene are monitored by real-time fluorescence quantitative polymerase chain reaction (PCR) and immunohistochemical staining. Finally, the animal models with knockdown of the target genes are analyzed phenotypically.
• Knock-out-based in vivo glycobiology disease model development service
  Our specialists first design suitable knockout vectors that contain DNA fragments with the knockout sequences and any necessary selection markers. Then, they use molecular cloning technology to build editing vectors that integrate the knock-out sequences of the target genes and ensure the stability and accuracy of the vectors. After confirming accurate integration of the knock-out sequences into the vector, the editing vector is administered to an animal model for in vivo gene editing using a gene delivery vector or gene editing tool. Subsequently, characterization and validation are performed on the edited animal model to confirm the successful knockout of the target gene. The edited animals are finally subjected to phenotyping.

Publication

Applications

• The established disease models are used in the identification of novel drug targets and the assessment of the effectiveness and safety of potential drugs.
• Glycobiological disease models are used to delve into the pathogenesis of diseases and to reveal key biological processes and signaling pathways.
• Glycobiological disease models are used in biomedical research to provide a key platform for understanding the nature of disease and for the development of individualized medicine.

Advantages

• Our gene editing technology precisely targets the target gene for modification, which achieves precise regulation of disease-related genes and simulates genetic variation or loss of gene function in the process of disease development.
• Our gene editing technology enables the control of the expression level of target genes and achieves quantitative regulation, thus more accurately simulating the changes in gene expression during disease development and contributing to an in-depth understanding of the pathogenesis of diseases.
• The gene editing technology at CD BioGlyco exhibits a high degree of flexibility and can be applied to different types of cells and animal models, providing researchers with a wealth of experimental options and research platforms.

CD BioGlyco provides a wide range of gene editing-based in vivo glycobiology disease model development services. We offer expertise in utilizing cutting-edge genome editing tools to precisely manipulate glycan-related genes in various animal species. If you are interested in our service, please don't hesitate to contact us.